These pieces of evidence demonstrate that the protective effects of EGCG against obesity induced inflammation and metabolic disorders are dose-response phenomena by controlling the acetylation state via the inhibition of HAT activity. This evidence concerns the gene TMPRSS11D and obesity due to melanocortin 4 receptor deficiency.